![]() The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including prostate, sarcomas and breast, reinforce the potential of its emerging CMBT(TM) pipeline.įor more information about the Company, visit and connect on Facebook, LinkedIn, and Twitter. The Company is currently focused on developing its novel compound, SM-88. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to cause cancer cell death. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients' quality of life through relatively low toxicity profiles. The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022. Management will address both live questions and those submitted in advance via email to. The webcastwill be accessible on the Events & Presentations page of the Investors section of the TYME website,, and will be archived for 90 days following the event.įollowing the Company's presentation, there will be a Q&A session. ![]() Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. ![]() This is my first DD ever, sorry if it sucks yall.BEDMINSTER, N.J. My positions: 110 shares at 2.06 avg (not much but I'm poor) You can see their presentation about it on their site.Īlso: This has a price target of $8-9 from numerous analysts. ![]() Something to note: TYME-18 treatment resulted in 11/12(91.6%) of established tumors resolving completely in mice, compared with ~16x mean growth in control treatment. If Tyme has good news to present, this stock will easily moon as this could change our view of cancer forever. With this in mind, why now? They are presenting today through Sunday at the American Society of Clinical Oncology 2021, and have already been in the 2nd and 3rd stage for a lot of their trials. Keep in mind I am not an expert, but this is what I am getting from researching this. In layman's terms, instead of targeting the cancer itself, they create an environment in your body that cancer can't live in (which eventually kills it). It's also important to note that they are targeting ADVANCED cancers, such as pancreatic cancer, which could be huge if they are successful. Instead of using targeted therapy for cancers, Tyme takes advantage of cancer cell's innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's immune system. Tyme Technologies (TYME), is a biotech company that focuses on developing cancer therapies. Hello everyone, you guys have helped me a lot recently so I wanted to share this with you before it's too late.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |